[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Andersen-Tawil syndrome (KCNJ2 mutation) with ventricular arrhythmias refractory to beta-blocker therapy is best managed with flecainide as add-on therapy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "This is Erdheim-Chester disease (non-Langerhans cell histiocytosis, CD68+, CD1a–, BRAF V600E+; manifestations include bone pain, exophthalmos, “hairy kidney” perirenal infiltration, osteosclerosis). BRAF V600E–mutated Erdheim-Chester disease is treated with BRAF inhibitor therapy such as vemurafenib.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Acute Fatty Liver of Pregnancy is strongly associated with a fetal deficiency of long-chain 3‑hydroxyacyl-CoA dehydrogenase (LCHAD), a disorder of mitochondrial fatty acid β-oxidation. Affected neonates are at risk of sudden death from hypoketotic hypoglycemia, cardiomyopathy, liver failure, and arrhythmias.\n\nThe appropriate screening test to prioritize is a **plasma acylcarnitine profile**, which detects characteristic elevations of long-chain hydroxyacylcarnitines seen in LCHAD and related fatty acid oxidation defects.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "High-dose ascorbic acid (vitamin C) is the best next step.\n\nIn G6PD deficiency, methylene blue is contraindicated because it requires NADPH (generated by G6PD) to be reduced to its active form; without this, it can worsen oxidative stress, hemolysis, and methemoglobinemia. After methylene blue–induced deterioration, further methylene blue (A) would be harmful.\n\nHigh-dose ascorbic acid (B) can non-enzymatically reduce methemoglobin and is used when methylene blue is contraindicated or ineffective. Exchange transfusion (C) is reserved for severe, refractory or life‑threatening cases; a level of 25% with deterioration after methylene blue in a young patient is better managed first with vitamin C. Hyperbaric oxygen (D) and hydroxocobalamin (E) are not standard therapies for methemoglobinemia in this setting.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This is Omenn syndrome: severe combined immunodeficiency with erythroderma, hepatosplenomegaly, chronic diarrhea, eosinophilia, elevated IgE, absence of B cells, and oligoclonal activated T cells, due to hypomorphic RAG1/RAG2 mutations.\n\nThe best answer is B. The answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Retrograde flow from the left coronary artery into the pulmonary artery is characteristic of ALCAPA, as the left coronary originates from the low-pressure pulmonary artery and blood is shunted back into it from collaterals. \n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical picture is C3 glomerulopathy (C3-dominant, low C3/normal C4, MPGN pattern) driven by a monoclonal gammopathy (abnormal free light chain ratio despite negative SPEP), i.e., MGRS (monoclonal gammopathy of renal significance). In this setting, the best strategy to preserve renal function is to treat the underlying clone with targeted chemotherapy rather than using only complement blockade or nonspecific immunosuppression.\n\nThe most appropriate treatment is clone-directed chemotherapy.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Reverse triggering is when a ventilator-initiated breath induces a diaphragmatic (patient) effort, often leading to breath stacking in a deeply sedated patient.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This is postpartum acquired hemophilia A (autoantibody to factor VIII): isolated prolonged aPTT, failure to correct on mixing study, and severely reduced factor VIII activity. For acute bleeding in acquired hemophilia A, first-line hemostatic therapy is a bypassing agent or recombinant porcine factor VIII, not human factor VIII (which is neutralized by the inhibitor). Among the options given, recombinant porcine factor VIII is the most appropriate first-line therapy for acute bleeding control.\n\nThe answer is (D)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This is describing Plasmodium knowlesi (Borneo, band forms like P. malariae but severe like P. falciparum). P. knowlesi has a 24-hour erythrocytic cycle.\n\nThe answer is (A)"}]